

Special Issue

Biomarkers and Pathogenesis of Infectious Diseases: From Research to Personalized Medicine

Message from the Guest Editor

Infectious diseases represent one of the main causes of morbidity and mortality worldwide. Currently, a cause of great concern is the emergence of multidrug-resistant bacteria. Early detection and effective therapy are the main goals to consider when an infected patient is being treated. The use of biomarkers for diagnosis and monitoring has potential, as they are promising clinical tools. New biomarkers related to infectious diseases have been tested, but few of them are used in clinical practice. Maybe bioinformatics or machine learning may develop prediction models for early detection and prognosis in terms of personalized medicine. This Special Issue aims to collate evidence about the physiopathology of infections, including advances in the detection and use of potential alternative personalized diagnostic strategies. We hope that this Special Issue will stimulate work on improving the methodologies for the detection and treatment of infections through providing comprehensive discussions so that we can achieve early diagnoses and thus reduce complications.

Guest Editor

Dr. César Henríquez-Camacho

1. Internal Medicine Specialist, Hospital Universitario de Mostoles, 28935 Madrid, Spain
2. Faculty of Medicine, Universidad Francisco de Vitoria (UFV), 28935 Madrid, Spain
3. Faculty of Medicine, Universidad Rey Juan Carlos, 28922 Madrid, Spain

Deadline for manuscript submissions

31 March 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/193727

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).